Subscribe to Entrepreneur for $5
Subscribe

Quidel Corporation (QDEL) Reports Solid Preliminary Q3 Revenues

Quidel's (QDEL) revenue growth in the third quarter is likely to have been boosted by robust sales of its SARS-related products.

By
This story originally appeared on Zacks

Quidel Corporation QDEL recently announced preliminary revenues for third-quarter 2021. The company expects to release detailed financial results for the period in November.

- Zacks

As per the preliminary report, third-quarter 2021 revenues are estimated to be in the range of $505-$510 million on a reported basis, up by around 6-7% from the year-ago quarter. The Zacks Consensus Estimate of $181.2 million remains below the preliminary figure.

The company’s COVID-19 revenues for the quarter are expected to be approximately $406 million, up by 8.1% from the year-ago quarter. Quidel also confirmed shipping more than 45 million SARS tests during the third quarter, reflecting an increase of 135% year over year.

Per the company, the strong revenue uptick in the third quarter resulted from a significant surge in demand throughout multiple markets for its SARS-related products on the back of continued rise in infections due to the spread of the highly contagious Delta variant.

Following this release, shares of the company are up 2.1% till the last trading.

A Brief Q3 Analysis

Quidel has been observing a robust adoption of its products over the past few months, which has driven up shipments of its SARS tests. The company, in early September, announced that it will soon make its non-prescription QuickVue At-Home OTC COVID-19 Test available to consumers. The test will be available at more than 7,000 CVS Health Corporation’s CVS pharmacy locations across the United States as well as online at cvs.com. In May, Quidel announced that its non-prescription QuickVue At-Home OTC COVID-19 Test will be available in the United States to consumers for online order through e-commerce retailer Amazon. These measures are likely to have driven the company’s robust sales of its SARS-related products during the third quarter.

Further, Quidel received the CE Mark for its Savanna multiplex molecular analyzer and Savanna RVP4 Assay (Respiratory Viral Panel-4) in July. This allows Quidel to market and sell the Savanna system in Europe as well as in countries that accept the CE Mark. In June, the company received an amended Emergency Use Authorization from the FDA, which allowed it to market Sofia Q, its latest addition to the Sofia and Sofia 2 line of Fluorescent Immunoassay Analyzers (“FIA”). Quidel, in May, received Health Canada’s authorization for its Sofia SARS Antigen FIA, to be used for serial testing in the detection of active coronavirus infection in both symptomatic and asymptomatic populations. The slew of regulatory approvals is expected to have significantly contributed to the company’s third-quarter revenues.

Although the company’s preliminary projection of a robust improvement in revenues lifts our confidence, management’s fear of the unstable SARS testing environment raises our apprehension.

Price Performance

Shares of the company have gained 12.7% in the past three months against the industry’s 4.2% fall and the S&P 500’s 0.5% rise.

Zacks Investment ResearchImage Source: Zacks Investment Research

Zacks Rank & Stocks to Consider

Currently, Quidel carries a Zacks Rank #5 (Strong Sell).

A couple of better-ranked stocks from the broader medical space are DexCom, Inc. DXCM and Omnicell, Inc. OMCL.

DexCom’s long-term earnings growth rate is estimated at 15.3%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Omnicell’s long-term earnings growth rate is estimated at 16%. It currently holds a Zacks Rank #2.



Tech IPOs With Massive Profit Potential

In the past few years, many popular platforms and like Uber and Airbnb finally made their way to the public markets. But the biggest paydays came from lesser-known names.

For example, electric carmaker X Peng shot up +299.4% in just 2 months. Think of it this way…

If you had put $5,000 into XPEV at its IPO in September 2020, you could have cashed out with $19,970 in November.

With record amounts of cash flooding into IPOs and a record-setting stock market, this year’s lineup could be even more lucrative.

See Zacks Hottest Tech IPOs Now >>



Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Omnicell, Inc. (OMCL): Free Stock Analysis Report

 

CVS Health Corporation (CVS): Free Stock Analysis Report

 

DexCom, Inc. (DXCM): Free Stock Analysis Report

 

Quidel Corporation (QDEL): Free Stock Analysis Report

 

To read this article on Zacks.com click here.

 

Zacks Investment Research